{"id":"W2587429794","doi":"10.1016/s1470-2045(17)30072-4","title":"Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":206,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia","funders":"Merck Sharp and Dohme; Bristol-Myers Squibb","keywords":"Vismodegib; Medicine; Basal cell carcinoma; Regimen; Placebo; Internal medicine; Population; Dosing; Basal Cell Nevus Syndrome; Oncology; Urology; Pathology; Basal cell","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high","status":"direct model label, unvalidated"}],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001195404,0.0003388997,0.001016612,0.00007194695,0.0004153599,0.00007525879,0.0007528324,0.0001972322,0.000007400103],"category_scores_gemma":[0.0002544248,0.0002204997,0.0001786836,0.00005146157,0.0003670616,0.00001223315,0.0003576865,0.0003261531,0.000009276608],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009871873,"about_ca_system_score_gemma":0.0001939638,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001488214,"about_ca_topic_score_gemma":0.0005043791,"domain_scores_codex":[0.997681,0.0004267548,0.0004924725,0.000578342,0.0002010598,0.0006203697],"domain_scores_gemma":[0.997757,0.0001631174,0.0006004334,0.001244785,0.0001412895,0.00009335068],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9757077,0.00104778,0.01081731,0.00001876891,0.0002432286,0.00003784745,0.0004729782,0.00009915038,0.009466964,0.00002097163,0.001110881,0.0009564454],"study_design_scores_gemma":[0.9794144,0.003040964,0.001799538,0.00003293505,0.0001275384,0.000004025308,0.0001084871,0.000145235,0.009705246,0.00001995483,0.005296466,0.0003051884],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9910029,0.0002748665,0.000197787,0.001085926,0.0005738672,0.002927904,0.00002306215,0.00001939832,0.003894346],"genre_scores_gemma":[0.9969759,0.00005147989,0.000300927,0.0005242735,0.001045297,0.0005742693,0.00006243935,0.0000447974,0.0004206142],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009017771,"threshold_uncertainty_score":0.8991715,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0508492730864267,"score_gpt":0.339065832435165,"score_spread":0.2882165593487384,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}